EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In relapsed or refractory diffuse large B‐cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine

Paolo F Caimi iD, Mehdi Hamadani, Carmelo Carlo-Stella iD, Masoud Nickaeen, Eric Jordie, Kiersten Utsey, Tim Knab, Francesca Zammarchi, Danilo Cucchi, Serafino Pantano, Karin Havenith iD, Ying Wang und 1 weitere

eJHaem · 2024-02 · 5 (1) · 76-83

DOI: 10.1002/jha2.816 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eJHaem, online erschienen am 30.11.2023. Verfasst von Paolo F Caimi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Blood and Marrow Transplant Program Taussig Cancer Institute Cleveland Clinic Foundation Cleveland Ohio USA. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CD19‐targeting treatments have shown promise in relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL). Loncastuximab tesirine (loncastuximab tesirine‐lpyl [Lonca]) is a CD19‐targeting antibody‐drug conjugate indicated for R/R DLBCL after at least two systemic treatments. CD19 expression was evaluated in patients receiving Lonca in the LOTIS‐2 clinical trial with available tissue samples obtained after last systemic therapy/before Lonca treatment. Lonca cytotoxicity was evaluated in a panel of six lymphoma cell lines with various CD19 expression levels. Quantitative systems pharmacology (QSP) modelling was used to predict Lonca responses. Lonca responses were seen in patients across all CD19 expression levels, including patients with low/no detectable CD19 expression and H‐scores at baseline. Similarly, Lonca induced cytotoxicity in cell lines with different levels of CD19 expression, including one with very low expression. QSP modelling predicted that CD19 expression by immunohistochemistry alone does not predict Lonca response, whereas inclusion of CD19 surface density improved response prediction. Virtual patients responded to Lonca with estimated CD19 as low as 1000 molecules/cell of CD19, normally below the immunohistochemistry detection level. We found Lonca is an effective treatment for R/R DLBCL regardless of CD19 expression by immunohistochemistry. These results provide the basis for future studies addressing CD19‐targeted agent sequencing.

Schlagwörter

Stichwörter der Autor:innen

CD19diffuse large B‐cell lymphomaimmunohistochemistryloncastuximab tesirinequantitative systems pharmacology

Autor:innen und Institutionen

  • Blood and Marrow Transplant Program Taussig Cancer Institute Cleveland Clinic Foundation Cleveland Ohio USA.
  • Division of Hematology and Oncology BMT and Cellular Therapy Program Medical College of Wisconsin Milwaukee Wisconsin USA.
  • Department of Biomedical Sciences Humanitas University and Department of Hematology and Oncology, IRCCS Humanitas Research Hospital Milan Italy.
  • Metrum Research Group Simsbury Connecticut USA.
  • ADC Therapeutics (United Kingdom) Ltd London UK.
  • ADC Therapeutics SA Épalinges Switzerland.

ORCID-Profile: Paolo F Caimi, Carmelo Carlo-Stella, Karin Havenith, Joseph Boni

Zitieren

APA

Caimi, P. F., Hamadani, M., Carlo-Stella, C., Nickaeen, M., Jordie, E., Utsey, K., Knab, T., Zammarchi, F., Cucchi, D., Pantano, S., Havenith, K., Wang, Y., & Boni, J. (2024). In relapsed or refractory diffuse large B‐cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine. eJHaem, 5(1), 76-83. https://doi.org/10.1002/jha2.816

Vancouver

Caimi PF, Hamadani M, Carlo-Stella C, Nickaeen M, Jordie E, Utsey K, et al. In relapsed or refractory diffuse large B‐cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine. eJHaem. 2024;5(1):76-83. doi:10.1002/jha2.816

BibTeX
@article{Caimi2024,
  author = {Caimi, Paolo F and Hamadani, Mehdi and Carlo-Stella, Carmelo and Nickaeen, Masoud and Jordie, Eric and Utsey, Kiersten and Knab, Tim and Zammarchi, Francesca and Cucchi, Danilo and Pantano, Serafino and Havenith, Karin and Wang, Ying and Boni, Joseph},
  title = {In relapsed or refractory diffuse large B‐cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine},
  journal = {eJHaem},
  year = {2024},
  volume = {5},
  number = {1},
  pages = {76--83},
  doi = {10.1002/jha2.816}
}
Kostenlos starten →